PIA-6

PIA-6 is a synthetic phosphatidylinositol ether lipid analog (PIA) that functions as an inhibitor of the AKT (Protein Kinase B) signaling pathway. Developed and studied by researchers at the National Cancer Institute (NCI), PIA-6 is part of a class of compounds designed to mimic the structure of phosphatidylinositol, thereby interfering with the recruitment of AKT to the plasma membrane and its subsequent activation. This inhibition disrupts the PI3K/AKT/mTOR signaling axis, which is a critical driver of cell proliferation, survival, and metabolism in various cancers. Preclinical research, including studies presented at the AACR, has evaluated PIA-6 for its anti-proliferative activity in glioblastoma and astrocytoma cell lines, particularly those with dysregulated signaling due to PTEN loss or receptor tyrosine kinase mutations.

Other names

Phosphatidylinositol ether lipid analog 6